李红良
心内
主任，二级教授，博士生导师
主任，二级教授，博士生导师
导师介绍
| 姓名 | 李红良 |
| 出生年月 | 1974年9月 |
| 单位 | 武汉大学人民医院心血管内科 |
| 所属学科 | 临床医学-内科学 |
| 职务、职称及头衔 | 主任，二级教授，博士生导师 |
| lihl@whu.edu.cn | |
| 联系方式 | 027-68759302 |
| 研究方向 |
1.心血管代谢性疾病的发生机制与防治。 2.基因敲除与转基因动物模型的研发。 |
| 个人简介 | 主要从事心血管代谢性疾病的基础研究和转化医学研究工作，获国家自然科学基金6项，科技部、省科技厅等课题30余项。已发表国际杂志论文200余篇，包括发表在国际知名杂志Nat Med, Cell Metabol, Circulation, Hepatology, J Hepatol, Nat Commun, Circ Res, Cardiovasc Res, Hypertension等，总引用超过10000次，并连续8年入选中国高被引学者榜单（医学）。申请国内发明专利200项。已培养硕士及博士毕业生40余名。 |
| 学术任职与荣誉 |
国家实验动物专家委员会委员 国家卫计委病原微生物实验室生物安全评审专家委员会委员 中国抗癌协会肿瘤分子医学专业委员会副主任委员 中国研究型医院学会心血管循证与精准医学专业委员会委员 中国实验动物学会小型猪专业委员会委员 中国实验动物学会实验动物福利伦理专业委员会委员 中国生物化学与分子生物学会脂质与脂蛋白委员会委员 湖北省实验动物学会第七届理事会副理事长 |
| 教育履历 |
1994.09-1999.07广东医学院临床医学专业本科生获学士学位 1999.09-2002.07暨南大学药理学专业硕士研究生获硕士学位 2002.09-2005.07中国协和医科大学生物化学与分子生物学博士研究生获博士学位 |
| 工作履历 |
2005.07-2006.02中国协和医科大学博士后 2006.02-2006.11哈佛大学医学院博士后 2006.11-2008.11加拿大多伦多大学博士后 2008.11-今 武汉大学第一临床学院 教授 2009-今湖北省模式动物研究中心主任 2013-2020 武汉大学模式动物协同创新中心主任 2015-2020武汉大学动物实验中心/ABSL- III实验室 主任 2016-2020武汉大学模式动物研究所所长 2017-2020武汉大学基础医学院院长 |
| 成果获奖 |
1.《心脑血管代谢疾病基因工程大小鼠模型的研发与应用》2016年湖北省科技进步一等奖 2.《心肌重构的发病基础与临床防治》2013年获湖北省科技进步一等奖 3.《心律失常的结构和神经重构的基础研究与临床防治》2011年获国家科学技术进步二等奖 |
| 代表性论著 |
1.Liu
J#, Li W#, Deng KQ#, Tian S#, Liu H, Shi H, Fang Q, Liu Z, Chen Z, Tian T,
Gan S, Hu F, Hu M, Cheng X, Ji YX, Zhang P, She ZG, Zhang XJ, Chen S, Cai J*,
Li H*. The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac
Hypertrophy. Circ Res. 2022 May 13;130(10):1586-1600. 2.Zhou J*#, Guo L#, Ma T#, Qiu T#, Wang S, Tian S, Zhang L, Hu F, Li W, Liu Z, Hu Y, Wang T, Kong C, Yang J, Zhou J*, Li H*. N-acetylgalactosaminyltransferase-4 protects against hepatic ischemia/reperfusion injury by blocking apoptosis signal-regulating kinase 1 N-terminal dimerization. Hepatology. 2022 Jun;75(6):1446-1460. 3.Chen Z#, Liu J#, Zhou F, Li H, Zhang XJ, She ZG, Lu Z, Cai J*, Li H*. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. Circ Res. 2021 May 28;128(11):1747-1765 4.Zhang XJ#, Liu X#, Hu M#, Zhao GJ#, Sun D, Cheng X, Xiang H, Huang YP, Tian RF, Shen LJ, Ma JP, Wang HP, Tian S, Gan S, Xu H, Liao R, Zou T, Ji YX, Zhang P, Cai J, Wang ZV, Meng G, Xu Q, Wang Y, Ma XL, Liu PP, Huang Z, Zhu L, She ZG, Zhang X, Bai L*, Yang H*, Lu Z*, Li H*. Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species. Cell Metab. 2021 Oct 5;33(10):2059-2075.e10. 5.Zhao GN#, Tian ZW#, Tian T#, Zhu ZP, Zhao WJ, Tian H, Cheng X, Hu FJ, Hu ML, Tian S, Ding T, Chen S, Ji YX, Zhang P, Zhang XJ, She ZG, Yuan Y*, Chen W*, Bai L*, Li H*. TMBIM1 is an inhibitor of adipogenesis and its depletion promotes adipocyte hyperplasia and improves obesity-related metabolic disease. Cell Metab. 2021 Aug 3;33(8):1640-1654.e8. 6.Ji YX*#, Wang Y#, Li PL#, Cai L#, Wang XM, Bai L, Liu Z, Tian H, Tian S, Zhang P, Zhang XJ, Cheng X, Yuan Y, She ZG*, Hu Y*, Li H*. A kinome screen reveals that Nemo-like kinase is a key suppressor of hepatic gluconeogenesis. Cell Metab. 2021 Jun 1;33(6):1171-1186.e9. 7.Cai J#, Li H#, Zhang C#, Chen Z#, Liu H#, Lei F, Qin JJ, Liu YM, Zhou F, Song X, Zhou J, Zhao YC, Wu B, He M, Yang H, Zhu L, Zhang P, Ji YX, Zhao GN, Lu Z, Liu L, Mao W, Liao X, Lu H, Wang D, Xia X, Huang X, Wei X, Xia J, Zhang BH, Yuan Y, She ZG, Xu Q, Ma X, Wang Y*, Yang J*, Zhang X*, Zhang XJ*, Li H*. The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19. Cell Metab. 2021 Feb 2;33(2):258-269.e3. 8.Wang W#, Hu M#, Liu H#, Zhang X#, Li H, Zhou F, Liu YM, Lei F, Qin JJ, Zhao YC, Chen Z, Liu W, Song X, Huang X, Zhu L, Ji YX, Zhang P, Zhang XJ, She ZG, Yang J*, Yang H*, Cai J*, Li H*. Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease. Cell Metab. 2021 Oct 5;33(10):1943-1956.e2. 9.Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, Lei F, Chen MM, Yang H, Bai L, Song X, Lin L, Xia M, Zhou F, Zhou J, She ZG, Zhu L, Ma X, Xu Q, Ye P, Chen G, Liu L, Mao W, Yan Y, Xiao B, Lu Z, Peng G, Liu M, Yang J, Yang L, Zhang C, Lu H, Xia X, Wang D, Liao X, Wei X, Zhang BH, Zhang X, Yang J, Zhao GN, Zhang P, Liu PP, Loomba R, Ji YX, Xia J, Wang Y, Cai J, Guo J, Li H*. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020 Jun 24:S1550-4131(20)30316-8. 10.Jian C, Fu J, Cheng X, Shen LJ, Ji YX, Wang X, Pan S, Tian H, Tian S, Liao R, Song K, Wang HP, Zhang X, Wang Y, Huang Z, She ZG, Zhang XJ*, Zhu L*, Li H*.Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. Cell Metab. 2020;31(5):892-908.e11. 11.Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, Lei F, Wang H, Xie J, Wang W, Li H, Zhang P, Song X, Chen X, Xiang M, Zhang C, Bai L, Xiang D, Chen MM, Liu Y, Yan Y, Liu M, Mao W, Zou J, Liu L, Chen G, Luo P, Xiao B, Zhang C, Zhang Z, Lu Z, Wang J, Lu H, Xia X, Wang D, Liao X, Peng G, Ye P, Yang J, Yuan Y*, Huang X*, Guo J*, Zhang BH*, Li H*.Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.Cell Metab. 2020:S1550-4131(20)30238-2. 12.Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, Zhang XJ, Cai J, Lin L, Ouyang S, Wang X, Yang C, Cheng X, Liu W, Li H, Xie J, Wu B, Luo H, Xiao F, Chen J, Tao L, Cheng G, She ZG, Zhou J, Wang H, Lin J, Luo P, Fu S, Zhou J, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu L, Chen G, Li H*, Huang X*, Zhang BH*, Yuan Y*.Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology. 2020 May 2. doi: 10.1002/hep.31301. 13.Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M, Chen MM, Cheng X, Zhang X, Guo D, Peng Y, Ji YX, Chen J, She ZG, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M, Chen M, Zhang XJ, Wang X, Touyz RM, Xia J, Zhang BH, Huang X, Yuan Y, Rohit L, Liu PP, Li H*. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19.Circ Res. 2020 Apr 17. doi: 10.1161/CIRCRESAHA.120.317134. 14.Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L*, Cai J*, Li H*. Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta-Analysis. Hepatology. 2019;70(4):1119-1133. 15.Cai J, Xu M, Zhang X, Li H*. Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases. Annu Rev Pathol. 2019 24;14:153-184. 16.Zhang XJ, Cheng X, Yan ZZ, Fang J, Wang XZ, Wang WJ, Liu ZY, Shen LJ, Zhang P, Wang PX, Liao RF, Ji YX, Wang JY, Tian S, Zhu XY, Zhang Y, Tian RF, Wang L, Ma XL, Huang Z, She ZG, Li H*, An ALOX12–12-HETE–GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury, Nat Med., 2018;24(1):73-83. 17.Zhang P, Wang PX, Zhao LP, Zhang X, Ji YX, Zhang XJ, Fang C, Lu YX, Yang X, Gao MM, Zhang Y, Tian S, Zhu XY, Gong J, Ma XL, Li F, Wang ZH, Huang Z, She ZG, Li H*, The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis. Nat Med., 2018;24(1):84-94. 18.Deng KQ, Li J, She ZG, Gong J, Cheng WL, Gong FH, Zhu XY, Zhang Y, Wang Z, Li H*. Restoration of Circulating MFGE8 (Milk Fat Globule-EGF Factor 8) Attenuates Cardiac Hypertrophy Through Inhibition of Akt Pathway. Hypertension. 2017; 70(4):770-779. 19.Zhang Y, Huang Z, Li H*. Insights into innate immune signaling in controlling cardiac remodeling. Cardiovasc Res. 2017, 113(13):1538-1550. 20.Wang ZH, Zhang XJ, Zhang P, Wang XH, Chen I, Gao C, Deng KQ, Gong J, Yokota T, Wang H, Cass A, Ren SX, Vondriska T, Li GP, Yang HT, Xiao XS, Li H*, Wang Y*, A long non- coding RNA defines an epigenetic check point for cardiac hypertrophy. Nat Med. 2016, 22(10):1131-1139. |
| Name | HONGLIANG LI |
| Date of birth | September，1974 |
| Department | Cardiovascular Department，Renmin Hospital,Wuhan University. |
| Title | Director, Professor, doctoral tutor |
| lihl@whu.edu.cn | |
| TEL | 027-68759302 |
| Research Direction |
1.
The mechanism and prevention of cardiometabolic diseases 2. Construction of genetic engineering animal model. |
| Personal Profile | Professor Li is mainly engaged in the basic research of cardiovascular and metabolic diseases and translational medicine research. He has obtained 6 National Natural Science Foundation of China, and more than 30 projects from the Ministry of Science and Technology and the Provincial Department of Science and Technology. Professor Li has published more than 200 papers in the internationally renowned journals, includingNat Med., Cell Metabol., Circulation, Hepatology, J Hepatol, Nat Commun., Circ Res, Cardiovasc Res, Hypertension,etc. The total number of citations is over 10000 times. He has been selected as one of the most cited scholars in China (medicine) for 8 consecutive years. Professor Li has applied for 200 domestic invention patents. More than 40 master and doctoral graduates have been trained. |
| Selected Publications |
1.Liu
J#, Li W#, Deng KQ#, Tian S#, Liu H, Shi H, Fang Q, Liu Z, Chen Z, Tian T,
Gan S, Hu F, Hu M, Cheng X, Ji YX, Zhang P, She ZG, Zhang XJ, Chen S, Cai J*,
Li H*. The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac
Hypertrophy. Circ Res. 2022 May 13;130(10):1586-1600. 2.Zhou J*#, Guo L#, Ma T#, Qiu T#, Wang S, Tian S, Zhang L, Hu F, Li W, Liu Z, Hu Y, Wang T, Kong C, Yang J, Zhou J*, Li H*. N-acetylgalactosaminyltransferase-4 protects against hepatic ischemia/reperfusion injury by blocking apoptosis signal-regulating kinase 1 N-terminal dimerization. Hepatology. 2022 Jun;75(6):1446-1460. 3.Chen Z#, Liu J#, Zhou F, Li H, Zhang XJ, She ZG, Lu Z, Cai J*, Li H*. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. Circ Res. 2021 May 28;128(11):1747-1765 4.Zhang XJ#, Liu X#, Hu M#, Zhao GJ#, Sun D, Cheng X, Xiang H, Huang YP, Tian RF, Shen LJ, Ma JP, Wang HP, Tian S, Gan S, Xu H, Liao R, Zou T, Ji YX, Zhang P, Cai J, Wang ZV, Meng G, Xu Q, Wang Y, Ma XL, Liu PP, Huang Z, Zhu L, She ZG, Zhang X, Bai L*, Yang H*, Lu Z*, Li H*. Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species. Cell Metab. 2021 Oct 5;33(10):2059-2075.e10. 5.Zhao GN#, Tian ZW#, Tian T#, Zhu ZP, Zhao WJ, Tian H, Cheng X, Hu FJ, Hu ML, Tian S, Ding T, Chen S, Ji YX, Zhang P, Zhang XJ, She ZG, Yuan Y*, Chen W*, Bai L*, Li H*. TMBIM1 is an inhibitor of adipogenesis and its depletion promotes adipocyte hyperplasia and improves obesity-related metabolic disease. Cell Metab. 2021 Aug 3;33(8):1640-1654.e8. 6.Ji YX*#, Wang Y#, Li PL#, Cai L#, Wang XM, Bai L, Liu Z, Tian H, Tian S, Zhang P, Zhang XJ, Cheng X, Yuan Y, She ZG*, Hu Y*, Li H*. A kinome screen reveals that Nemo-like kinase is a key suppressor of hepatic gluconeogenesis. Cell Metab. 2021 Jun 1;33(6):1171-1186.e9. 7.Cai J#, Li H#, Zhang C#, Chen Z#, Liu H#, Lei F, Qin JJ, Liu YM, Zhou F, Song X, Zhou J, Zhao YC, Wu B, He M, Yang H, Zhu L, Zhang P, Ji YX, Zhao GN, Lu Z, Liu L, Mao W, Liao X, Lu H, Wang D, Xia X, Huang X, Wei X, Xia J, Zhang BH, Yuan Y, She ZG, Xu Q, Ma X, Wang Y*, Yang J*, Zhang X*, Zhang XJ*, Li H*. The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19. Cell Metab. 2021 Feb 2;33(2):258-269.e3. 8.Wang W#, Hu M#, Liu H#, Zhang X#, Li H, Zhou F, Liu YM, Lei F, Qin JJ, Zhao YC, Chen Z, Liu W, Song X, Huang X, Zhu L, Ji YX, Zhang P, Zhang XJ, She ZG, Yang J*, Yang H*, Cai J*, Li H*. Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease. Cell Metab. 2021 Oct 5;33(10):1943-1956.e2. 9.Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, Lei F, Chen MM, Yang H, Bai L, Song X, Lin L, Xia M, Zhou F, Zhou J, She ZG, Zhu L, Ma X, Xu Q, Ye P, Chen G, Liu L, Mao W, Yan Y, Xiao B, Lu Z, Peng G, Liu M, Yang J, Yang L, Zhang C, Lu H, Xia X, Wang D, Liao X, Wei X, Zhang BH, Zhang X, Yang J, Zhao GN, Zhang P, Liu PP, Loomba R, Ji YX, Xia J, Wang Y, Cai J, Guo J, Li H*. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020 Jun 24:S1550-4131(20)30316-8. 10.Jian C, Fu J, Cheng X, Shen LJ, Ji YX, Wang X, Pan S, Tian H, Tian S, Liao R, Song K, Wang HP, Zhang X, Wang Y, Huang Z, She ZG, Zhang XJ*, Zhu L*, Li H*.Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. Cell Metab. 2020;31(5):892-908.e11. 11.Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, Lei F, Wang H, Xie J, Wang W, Li H, Zhang P, Song X, Chen X, Xiang M, Zhang C, Bai L, Xiang D, Chen MM, Liu Y, Yan Y, Liu M, Mao W, Zou J, Liu L, Chen G, Luo P, Xiao B, Zhang C, Zhang Z, Lu Z, Wang J, Lu H, Xia X, Wang D, Liao X, Peng G, Ye P, Yang J, Yuan Y*, Huang X*, Guo J*, Zhang BH*, Li H*.Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.Cell Metab. 2020:S1550-4131(20)30238-2. 12.Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, Zhang XJ, Cai J, Lin L, Ouyang S, Wang X, Yang C, Cheng X, Liu W, Li H, Xie J, Wu B, Luo H, Xiao F, Chen J, Tao L, Cheng G, She ZG, Zhou J, Wang H, Lin J, Luo P, Fu S, Zhou J, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu L, Chen G, Li H*, Huang X*, Zhang BH*, Yuan Y*.Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology. 2020 May 2. doi: 10.1002/hep.31301. 13.Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M, Chen MM, Cheng X, Zhang X, Guo D, Peng Y, Ji YX, Chen J, She ZG, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M, Chen M, Zhang XJ, Wang X, Touyz RM, Xia J, Zhang BH, Huang X, Yuan Y, Rohit L, Liu PP, Li H*. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19.Circ Res. 2020 Apr 17. doi: 10.1161/CIRCRESAHA.120.317134. 14.Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L*, Cai J*, Li H*. Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta-Analysis. Hepatology. 2019;70(4):1119-1133. 15.Cai J, Xu M, Zhang X, Li H*. Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases. Annu Rev Pathol. 2019 24;14:153-184. 16.Zhang XJ, Cheng X, Yan ZZ, Fang J, Wang XZ, Wang WJ, Liu ZY, Shen LJ, Zhang P, Wang PX, Liao RF, Ji YX, Wang JY, Tian S, Zhu XY, Zhang Y, Tian RF, Wang L, Ma XL, Huang Z, She ZG, Li H*, An ALOX12–12-HETE–GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury, Nat Med., 2018;24(1):73-83. 17.Zhang P, Wang PX, Zhao LP, Zhang X, Ji YX, Zhang XJ, Fang C, Lu YX, Yang X, Gao MM, Zhang Y, Tian S, Zhu XY, Gong J, Ma XL, Li F, Wang ZH, Huang Z, She ZG, Li H*, The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis. Nat Med., 2018;24(1):84-94. 18.Deng KQ, Li J, She ZG, Gong J, Cheng WL, Gong FH, Zhu XY, Zhang Y, Wang Z, Li H*. Restoration of Circulating MFGE8 (Milk Fat Globule-EGF Factor 8) Attenuates Cardiac Hypertrophy Through Inhibition of Akt Pathway. Hypertension. 2017; 70(4):770-779. 19.Zhang Y, Huang Z, Li H*. Insights into innate immune signaling in controlling cardiac remodeling. Cardiovasc Res. 2017, 113(13):1538-1550. 20.Wang ZH, Zhang XJ, Zhang P, Wang XH, Chen I, Gao C, Deng KQ, Gong J, Yokota T, Wang H, Cass A, Ren SX, Vondriska T, Li GP, Yang HT, Xiao XS, Li H*, Wang Y*, A long non- coding RNA defines an epigenetic check point for cardiac hypertrophy. Nat Med. 2016, 22(10):1131-1139. |
武汉大学人民医院
湖北省人民医院